Knoxville, TN, United States of America

Jianjun Chen



 

Average Co-Inventor Count = 5.9

ph-index = 4

Forward Citations = 62(Granted Patents)


Location History:

  • Memphis, TN (US) (2013 - 2016)
  • Knoxville, TN (US) (2018 - 2020)

Company Filing History:


Years Active: 2013-2020

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Jianjun Chen

Introduction

Jianjun Chen is a prominent inventor based in Knoxville, TN, known for his significant contributions to cancer treatment through innovative compounds. With a total of 8 patents to his name, Chen has made strides in the pharmaceutical field, particularly in developing effective therapies for various forms of cancer.

Latest Patents

Among his latest patents, Chen has developed compounds aimed at treating cancer. One notable invention relates to a compound of formula XXII and a compound of formula 17ya, which are utilized in compositions for treating various forms of cancer. Another significant patent involves pharmaceutical compositions that include BRAF inhibitors, such as vemurafenib, and MEK inhibitors, like trametinib and RO5068760. These compositions are designed to work in conjunction with anti-tubulin compounds to treat conditions such as melanoma, drug-resistant cancer, and cancer metastasis.

Career Highlights

Throughout his career, Jianjun Chen has worked with esteemed organizations, including the University of Tennessee Research Foundation and GTx Corporation. His work in these institutions has allowed him to focus on groundbreaking research and development in cancer therapies.

Collaborations

Chen has collaborated with notable colleagues, including Wei Li and Duane Douglas Miller, contributing to a rich environment of innovation and discovery in the field of cancer treatment.

Conclusion

Jianjun Chen's work exemplifies the impact of innovative thinking in the medical field, particularly in the fight against cancer. His patents and collaborations highlight his commitment to advancing treatment options for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…